If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
=== Volcanic ash in the ocean === Geoffrey W. Hoffmann has argued that a complex nucleation event as the origin of life involving both polypeptides and nucleic acid is compatible with the time and space available in the primary oceans of Earth. Hoffmann suggests that volcanic ash may provide the many random shapes needed in the postulated complex nucleation event. This aspect of the theory can be tested experimentally.
The figures provided in this section on epidemiology all refer to undernutrition even if the term malnutrition is used which, by definition, could also apply to too much nutrition. The Global Hunger Index (GHI) is a multidimensional statistical tool used to describe the state of countries' hunger situation. The GHI measures progress and failures in the global fight against hunger. The GHI is updated once a year. The data from the 2015 report shows that Hunger levels have dropped 27% since 2000. Fifty two countries remain at serious or alarming levels. In addition to the latest statistics on Hunger and Food Security, the GHI also features different special topics each year. The 2015 report include an article on conflict and food security.
The legendary religious zeal of the Normans was exercised in religious wars long before the First Crusade carved out a Norman principality in Antioch. They were major foreign combatants in the Reconquista in Iberia. In 1018, Roger de Tosny travelled to the Iberian Peninsula to carve out a state for himself from Moorish lands, but failed. In 1064, during the War of Barbastro, William of Montreuil, Roger Crispin and probably Walter Guiffard led an army under the papal banner which took a huge booty as they captured the city from its Andelusi rulers. Later a group of Normans led by a certain William (some have suggested this was William the Carpenter) participated in the failed siege of Tudela of 1087. In 1096, Crusaders passing by the siege of Amalfi were joined by Bohemond of Taranto and his nephew Tancred with an army of Italo-Normans. Bohemond was the de facto leader of the Crusade during its passage through Asia Minor. After the successful Siege of Antioch in 1097, Bohemond began carving out an independent principality around that city. Tancred was instrumental in the conquest of Jerusalem and he worked for the expansion of the Crusader kingdom in Transjordan and the region of Galilee.. After the First Crusade to the Levant, the Normans continued with their involvement in Iberia as well as other areas of the Mediterranean. Among them was Rotrou of Perche and his followers Robert Burdet and William Giffard who joined multiple expeditions into the Ebro Valley to aid Alfonso I of Aragon in his campaigns of conquest.
The neck of the emu is pale blue and shows through its sparse feathers. They have grey-brown plumage of shaggy appearance; the shafts and the tips of the feathers are black. Solar radiation is absorbed by the tips, and the inner plumage insulates the skin. This prevents the birds from overheating, allowing them to be active during the heat of the day. A unique feature of the emu feather is the double rachis emerging from a single shaft. Both of the rachis have the same length, and the texture is variable; the area near the skin is rather furry, but the more distant ends resemble grass. The sexes are similar in appearance, although the male's penis can become visible when he urinates and defecates. The plumage varies in colour due to environmental factors, giving the bird a natural camouflage. Feathers of emus in more arid areas with red soils have a rufous tint while birds residing in damp conditions are generally darker in hue. The juvenile plumage develops at about three months and is blackish finely barred with brown, with the head and neck being especially dark. The facial feathers gradually thin to expose the bluish skin. The adult plumage has developed by about fifteen months. The eyes of an emu are protected by nictitating membranes. These are translucent, secondary eyelids that move horizontally from the inside edge of the eye to the outside edge. They function as visors to protect the eyes from the dust that is prevalent in windy arid regions. Emus have a tracheal pouch, which becomes more prominent during the mating season.
Sources: en.wikipedia.org
Progestogens alone are in general able to suppress testosterone levels in men by a maximum of about 70 to 80%, or to just above female/castrate levels when used at sufficiently high doses. The combination of a sufficient dosage of a progestogen with very small doses of an estrogen (e.g., as little as 0.5–1.5 mg/day oral estradiol) is synergistic in terms of antigonadotropic effect and is able to fully suppress gonadal testosterone production, reducing testosterone levels to the female/castrate range.
=== Buses === Bromley is served by London Buses routes 61, 119, 126, 138, 146, 162, 208, 227, 246, 261, 269, 314, 320, 336, 352, 354, 358, 367, 638, N3, N199, SL3 and SL5. These connect it with areas including Beckenham, Bexley, Bexleyheath, Biggin Hill, Catford, Chislehurst, Croydon, Crystal Palace, Downham, Elmers End, Eltham, Grove Park, Hayes, Lee Green, Lewisham, Locksbottom, Mottingham, New Addington, Orpington, Penge, Petts Wood, Sidcup, West Wickham & Westerham.
The oldest definitive evidence for fire making (i.e. igniting a new fire) dates to ~400,000 years ago at a Neanderthal site in Suffolk, England, where burnt soil was found along with fire-cracked flint handaxes and two fragments of iron pyrite, used to strike sparks with flint. At other sites in France dating from 50,000 years ago onwards, dozens of Neanderthal hand axes exhibit use-wear traces suggesting they were struck with pyrite to produce sparks. Ötzi, a well-preserved natural mummy of a man who lived in the Ötztal Alps between 3350 and 3105 BCE, carried fire-making material in the form of tinder fungus with flint and pyrite for creating sparks. The Kaurna people of South Australia have used pyrite with flintstone and a form of tinder made of stringybark as a traditional method of starting fires. Pyrite has been used since classical times to manufacture copperas (ferrous sulfate). Iron pyrite was heaped up and allowed to weather (an example of an early form of heap leaching). The acidic runoff from the heap was then boiled with iron to produce iron sulfate. In the 15th century, new methods of such leaching began to replace the burning of sulfur as a source of sulfuric acid. By the 19th century it had become the dominant method. Marcasite jewelry, using small faceted pieces of pyrite, often set in silver, has been made since ancient times and was popular in the Victorian era.
Sources: en.wikipedia.org
=== Sports === The regulation of modafinil as a doping agent has been controversial in sport since several American athletes tested positive for the substance. Some athletes who used modafinil protested that it was not on the prohibited list at the time of their offenses. However, the World Anti-Doping Agency (WADA) maintains that modafinil was related to already-banned substances. The Agency added modafinil to its list of prohibited substances on August 3, 2004, ten days before the start of the 2004 Summer Olympics. Several athletes across track and field, cycling, basketball, and rowing have tested positive for modafinil and faced sanctions, with some cases resulting in stripped medals and bans. The BALCO scandal brought to light an unsubstantiated (but widely published) account of Major League Baseball's all-time leading home-run hitter Barry Bonds' supplemental chemical regimen that included modafinil in addition to anabolic steroids and human growth hormone.
Buspirone acts primarily on the serotonin 5-HT1A receptor. It behaves as a full agonist at presynaptic 5-HT1A autoreceptors in the dorsal raphe, reducing the firing of serotonin-producing neurons, and as a partial agonist at postsynaptic 5-HT1A receptors in forebrain regions. This difference in activity between presynaptic and postsynaptic sites is thought to result from variations in receptor density and coupling efficiency. Buspirone also has lower affinity for other serotonin receptors, including 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7, where it is thought to act primarily as an antagonist. In addition, buspirone has weak antagonistic activity at dopamine D2, D3, and D4 receptors, with preferential blockade of presynaptic D2 autoreceptors at low doses and postsynaptic D2 receptors only at higher doses. A major metabolite of buspirone, 1-(2-pyrimidinyl)piperazine (1-PP), circulates at higher levels than buspirone itself and is a potent α2-adrenergic receptor antagonist, which may contribute to some of buspirone's noradrenergic and dopaminergic effects. Buspirone has very weak affinity for α1-adrenergic receptors, and does not interact with the GABAA receptor. Buspirone has been found to produce antiaggressive effects in rodents. It can strongly increase oxytocin levels in rodents, maximally by up to 9-fold. Conversely, the drug did not affect oxytocin levels in humans, though it enhanced hypoglycemia-induced oxytocin elevation.
=== Resistance === Strains of the Trypanosoma brucei parasite that are resistant to pentamidine have been discovered. Pentamidine is brought into the mitochondria through carrier proteins, and the absence of these carriers prevents the drug from reaching its site of action.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.